• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
Veterinary Heroes
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Cannabinoid Animal Drug Advances to Next Phase of Development

August 6, 2018
Amanda Carrozza

Results from a pharmacokinetic and safety study of the first cannabinoid-based pain medication have been positive, and the next phase of the study is set to begin.

(August 6) — CannPal Animal Therapeutics has received ethics approval to advance the development of CPAT-01—a cannabinoid drug intended to control pain in dogs.

The company will now move into phase 1B of the drug’s pharmacokinetic and safety study.

“The speed with which CannPal has moved to the next stage of our research is indicative of our commitment to progressing our clinical development plans on time,” CannPal Managing Director Layton Mills said.

For phase 1B, slated to start this month, the company has recruited 48 dogs to help them assess additional pharmacokinetic and safety parameters of the drug—including tolerability at 5 times the estimated dose, early dose ranging confirmation, and the cannabinoid impact on identified gene expression targets.

Advertisement

CannPal expects to report results of the study in Q3 of this year.

(June 30) — The use of cannabinoids in veterinary medicine has been a much discussed and debated topic as of late. As more pet owners become curious about the potential benefits of cannabinoid-based products for their pets—from pain support to anxiety relief—veterinarians have been tasked with delving further into the research and education available on the topic. And the race is on to get cannabinoid-based products to market.

The 2 most well-known cannabinoids are cannabidiol (CBD) and tetrahydrocannabinol (THC). To date, all animal-based cannabinoid products contain only CBD. Phyto Animal Health, for example, has a robust line of CBD products that includes tinctures and bedding, and CBD Health Co., a traditionally human-focused company, started offering a line of hemp-based products for pets earlier this year.

RELATED:

  • Veterinary-Exclusive CBD Product
  • Medical Marijuana Research Remains Top Priority for Veterinarians

Most recently, CannPal Animal Therapeutics, an Australian firm, received favorable results from a pharmacokinetic and safety study for a cannabinoid drug intended to control pain in dogs. This "first-in-dog use" proprietary oral cannabinoid formulation, known as CPAT-01, contains both CBD and THC .

The phase 1A study was conducted on 11 male beagles—8 treated and 3 control—of varied ages and weights. The results indicated excellent safety profiles seen at the initial target dose, no adverse events, and significant absorption in its current formulation.

The study’s success opens the door for CannPal to proceed with preparation for phase 1b of the study, with 48 dogs, which is expected to commence in the fall. According to an interview with AnimalPharm, the company anticipates that the product could be ready for commercialization in 2021.

Now that the CPAT-01 studies are underway in dogs, the company is exploring how to expand the drug to also be used in cats, which CannPal calls “a significantly unmet need in the companion animal drug market.”


Advertisement

Latest News

The four-letter word to why you're burning out and feeling unproductive

Merck Manuals recognizes importance of One Health concept

Topical therapy and immunotherapy can save time and frustration with dermatology cases

Texas Tech appoints new faculty member with passion for animal agriculture

View More Latest News
Advertisement